ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET.
Management will provide a business update, including preliminary 2023 revenue and cash position, as well as other operational highlights during the call. In addition, the Company will discuss the upcoming Share Consolidation (“reverse stock split”) and other matters related to a Special Virtual-Only Meeting of Shareholders to be held on February 28, 2024, at 1:00 p.m. ET.
A question-and-answer session will follow management’s prepared remarks.
Event: Zomedica Business Update Call
Date: Wednesday, January 17, 2024
Time: 4:30 p.m. Eastern Time
Live Call: 1-877-407-0789 (U.S. Toll Free) or 1-201-689-8562 (International)
Webcast: Zomedica Business Update Webcast
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Wednesday, January 31, 2024, at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13743242.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit zomedica.com.
Follow Zomedica
Investor Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…